Palvella Therapeutics, Inc. (PVLA) Net margin 2016–2023
Palvella Therapeutics, Inc. (PVLA) net profit margin by fiscal year — reported net income divided by reported revenue.
43.7%FY2023 · since FY2016: -391.0% → 43.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | 43.7% | +172.1 pp |
| FY2022 | -128.5% | +17.1 pp |
| FY2021 | -145.6% | -18.6 pp |
| FY2020 | -127.0% | -68.6 pp |
| FY2019 | -58.4% | +39.8 pp |
| FY2018 | -98.2% | -28.4 pp |
| FY2017 | -69.8% | +321.2 pp |
| FY2016 | -391.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More PVLA financial trends
PVLA RevenuePVLA Net incomePVLA Gross profitPVLA Gross marginPVLA Operating incomePVLA Operating marginPVLA Operating cash flowPVLA Free cash flowPVLA Capital expendituresPVLA Return on equityPVLA Stock buybacksPVLA Dividends paidPVLA Total assetsPVLA Total liabilitiesPVLA Shareholders’ equityPVLA overview →